Answers are grounded in this paper and cite their sources.
Retrospective comparison investigates immunosuppressive therapy's effectiveness in elderly AAV patients, suggesting tailored treatment may reduce risks.
Antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis (AAV) predominantly affects elderly individuals and often presents with rapidly progressive glomerulonephritis (RPGN). The standard treatment consists of corticosteroids combined with immunosuppressive agents. However, in elderly patients, adverse events such as severe infections are major concerns, and tailoring treatment intensity is essential.
No takes yet. Share an insight, caveat, or question.
Watanabe et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: